Brief: Vyloy (Zolbetuximab) Now Funded In Ontario And Quebec For Advanced Gastric Cancer
01/10/2025 14:55
Oct 1 (Reuters) - Astellas Pharma Inc 4503.T: VYLOY® (ZOLBETUXIMAB) IN COMBINATION WITH CHEMOTHERAPY FOR ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER IS NOW FUNDED IN BOTH ONTARIO AND QUEBEC Source text: ID:nCNWHy0pMa Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn